

Panitumumab PRIME

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Panitumumab PRIME

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers  
 Therapeutic Indication: First-line treatment of patients with wild-type RAS mCRC  
 Experimental Arm: Panitumumab + FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)  
 Control Arm: FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin)

